December 13, 2017
Pioglitazone effectively reduced nonalcoholic fatty liver disease activity score in patients with nonalcoholic steatohepatitis with and without type 2 diabetes, according to a recently published study. Pioglitazone also reduced liver fibrosis in patients with type 2 diabetes, but increased adipose tissue insulin sensitivity.
“These results suggest that pioglitazone may provide the same metabolic and histologic benefits to patients with NASH and prediabetes and to those with NASH and [type 2 diabetes],” Fernando Bril, MD, from the University of Florida, and colleagues wrote. “Greater improvements in resolution of NASH may suggest specific pioglitazone mechanisms in the [type 2 diabetes] population. While the effects on fibrosis appear to be similar in both groups, pioglitazone may contribute to halt the rapid progression observed in this group.”